GlassScriptPhysician profile
Ronald M Long
NPI 1013971654
$8,170.30
in general payments reported to CMS, 2019-2025
27 companies · $570 in 2025
The $570 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $449 · 2021: $573 · 2022: $1,009 · 2023: $3,954 · 2024: $1,201 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,836 · Travel and Lodging: $1,889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,836.46 |
| Travel and Lodging | $1,888.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $3,177.28 | 2023 | Intracept |
| Abbott Laboratories | $2,499.76 | 2019-2025 | Proclaim, Eterna, Octrode |
| Spr Therapeutics, INC | $429.75 | 2021-2025 | Sprint Pns System |
| Boston Scientific Corporation | $345.17 | 2024-2025 | Intracept, Artisan |
| Collegium Pharmaceutical, INC. | $266.40 | 2019-2024 | Belbuca, Xtampza |
| Medtronic, INC. | $204.58 | 2021-2025 | Inceptiv, Intellis Adaptivestim |
| Abbvie INC. | $191.79 | 2023-2024 | |
| Valinor Pharma, LLC | $135.96 | 2023-2025 | Movantik |
| Scilex Pharmaceuticals INC. | $101.44 | 2019-2022 | |
| Pfizer INC. | $88.29 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $86.29 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.82 | 2019-2023 | Relistor |
| Virtus Pharmaceuticals LLC | $80.00 | 2024 | Levorphanol Tartrate |
| Arbor Pharmaceuticals, INC. | $67.89 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $60.74 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $53.40 | 2023-2024 | Mild Device Kit |
| Si-Bone, INC. | $51.58 | 2023-2025 | |
| Redhill Biopharma INC. | $46.11 | 2020-2021 | |
| Almatica Pharma LLC | $34.37 | 2021-2022 | |
| Daiichi Sankyo INC. | $31.85 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $31.01 | 2025 | |
| Averitas Pharma INC. | $23.66 | 2023 | Qutenza |
| Lilly USA, LLC | $20.65 | 2025 | Zepbound, Mounjaro |
| Ultragenyx Pharmaceutical INC. | $17.59 | 2022 | |
| Zimmer Biomet Holdings, INC. | $15.20 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.56 | 2024 | Horizant |
| Astrazeneca Pharmaceuticals LP | $14.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.